Boehringer Ingelheim rearranges board of directors

Boehringer Ingelheim has announced a number of changes to the membership of its board of managing directors.

Engelbert Tjeenk Willink, the board member responsible for marketing and sales of prescription medicines, will be leaving the company at the end of 2012, with Alan Hillgrove named as his successor.

Mr Hillgrove is an Australian national who has been with Boehringer Ingelheim since 1982 and has worked as head of established markets since 2010, playing a key role in various corporate growth initiatives.

The company thanked the outgoing Mr Tjeenk Willink for his contributions to the business.

Chairman of the shareholders committee Christian Boehringer and board chairman Professor Andreas Barner said: "With this staffing arrangement, the board of managing directors will be well equipped for the various challenges that lie ahead for Boehringer Ingelheim and the research-driven pharmaceutical industry worldwide."

Last week, the company announced that it has completed enrolment for a pair of phase III trials of nintedanib, a new therapy for idiopathic pulmonary fibrosis.